GLPBio

Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)

Catalog No.: GC92134Purity:>95.00%Synonyms: Gastric Inhibitory Peptide; GIP
Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt) 포도당에 반응하여 인슐린 분비를 유도하는 내인성 42 아미노산 펩타이드 인크레틴 호르몬이다.

제품은 연구용으로만 사용됩니다. 인체에 사용할 수 없으며 환자에게 판매하지 않습니다.


Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)
1 mgIn Stock
$419.00
1

인용 문헌 (Citations)

현재 이 제품에 대한 인용 문헌이 없습니다. 아래는 GlpBio 제품을 인용한 주요 논문입니다.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

제품 설명 (Description)

Glucose-dependent Insulinotropic Polypeptide (GIP) (human) is an endogenous 42-amino acid peptide incretin hormone that induces insulin secretion in response to glucose.1 It belongs to the secretin/glucagon superfamily of peptides, which includes secretin, glucagon, glucagon-like peptide-1 (GLP-1, GLP-2), and pituitary adenylate cyclase-activating polypeptide (PACAP).2 GIP is a GIP receptor agonist that binds to rat recombinant GIP receptors expressed in CHO-K1 cells (IC50 = 3.2 nM) and increases cAMP accumulation (EC50 = 377 pM).3 It stimulates insulin secretion from BRIN-BD11 rat pancreatic β-cells when used at a concentration of 10 nM.4 GIP (1 pmol/min per 100 g) decreases blood glucose level and increases plasma insulin level in rats following glucose challenge.3 It also decreases plasma glucose level and increases insulin level in ob/ob mice following glucose challenge when administered at a dose of 25 nmol/kg.5

References:
[1]. Baggio, L.L., and Drucker, D.J.Biology of incretins: GLP-1 and GIPGastroenterology132(6)2131-2157(2007).
[2]. Vaudry, D., Falluel-Morel, A., Bourgault, S., et al.Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discoveryPharmacol. Rev.61(3)283-357(2009).
[3]. Hinke, S.A., Manhart, S., Pamir, N., et al.Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)Biochim. Biophys. Acta1547(1)143-155(2001).
[4]. Kerr, B.D., Flatt, A.J., Flatt, P.R., et al.Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptideBiochem. Biophys. Res. Commun.404(3)870-876(2011).
[5]. O'Harte, F.P., Hunter, K., Gault, V.A., et al.Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob miceAm. J. Physiol. Endocrinol. Metab.292(6)E1674-E1682(2007).

제품 문서 (Product Documents)

Purity:>95.00%Appearance:A solid

화학적 특성 (Chemical Properties)

동의어
Gastric Inhibitory Peptide; GIP
화학명
L-tyrosyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-isoleucyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-L-alanyl-L-methionyl-L-α-aspartyl-L-lysyl-L-isoleucyl-L-histidyl-L-glutaminyl-L-glutaminyl-L-α-aspartyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-leucyl-L-alanyl-L-glutaminyl-L-lysylglycyl-L-lysyl-L-lysyl-L-asparaginyl-L-α-aspartyl-L-tryptophyl-L-lysyl-L-histidyl-L-asparaginyl-L-isoleucyl-L-threonyl-L-glutamine, trifluoroacetate salt
SMILES
[H]N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@@H](C)O)([H])C(N[C@H](C(N[C@]([C@H](CC)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@]([C@H](CC)C)([H])C(N[C@]([C@@H](C)O)([H])C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)CC1=CN=CN1)=O)=O)CC2=CNC3=C2C=CC=C3)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC4=CNC5=C4C=CC=C5)=O)=O)=O)CC6=CC=CC=C6)=O)CC(O)=O)=O)=O)=O)CC7=CN=CN7)=O)=O)=O)CC(O)=O)=O)CCSC)=O)C)=O)=O)=O)CC8=CC=C(O)C=C8)=O)CC(O)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)C)=O)CC%10=CC=C(O)C=C%10.FC(F)(C(O)=O)F
분자식
C226H338N60O66S ? XCF3COOH
분자량
4983.5
용해도
Water: 1 mg/ml
보관
-20°C
일반 주의사항
제품의 용해도 데이터에 따라 적절한 용매를 선택하십시오. 조제 후에는 반복적인 동결·해동을 피할 수 있도록 저장 용액을 소분하십시오.
저장 용액은 -80°C 보관 시 6개월 이내, -20°C 보관 시 1개월 이내에 사용하십시오.
용해도를 높이려면 튜브를 37°C로 데운 뒤 적절한 시간 동안 초음파 처리하십시오.
배송 조건
평가용 샘플은 아이스팩과 함께 배송됩니다. 그 외 용량은 실온 배송되며, 요청 시 아이스팩과 함께 배송할 수 있습니다.

계산 도구 (Calculators)몰 농도 / 희석 / 분자량 / 단위 변환 / 생체 내 제형 / 용해도

g/mol

Reviews

Review for Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%